Skip to content
Parakho

Neuland Laboratories Ltd

NSE NEULANDLABBSE 524558neulandlabs.comInvestor relations

Q1 FY27, unaudited

Revenue
₹641.58 Cr
Profit after tax
₹147.36 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations641.58+119.15%2,022.99
Other income8.49+8.09%30.16
Total income650.07+116.25%2,053.15
Employee benefit expense103.02+45.35%328.82
Finance costs6.97+52.12%23.95
Depreciation & amortisation26.56+31.57%91.73
Total expenses452.53+59.78%1,565.42
Profit before tax197.54+1,036.70%487.73
Tax expense50.17+1,266.99%124.63
Profit after tax147.36+975.04%363.11
Total comprehensive income147.36+975.04%363.46
Earnings per share
Earnings per share, basic₹114.86₹283.01
Earnings per share, diluted₹114.86₹283.01

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Neuland Laboratories reported total income of INR650.1 crores for Q1FY27, up 16.3% year-on-year, with EBITDA margin at 35.5% and PAT of INR147.4 crores compared to INR13.7 crores a year earlier. Management attributed growth primarily to commercial CMS projects and a favorable customer mix, while working capital days improved from 137 to 84. The company also discussed a strategic collaboration with Gland Pharma for sterile API manufacturing and progress on its peptide manufacturing facility, which is expected to be commissioned the following month.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 62 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 05 Oct 2026.